The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study. Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Flinn, Ian W., Burger, Jan A., Tran, Anh, Clow, Fong, James, Danelle F., Graef, Thorsten, Friedberg, Jonathan W., Rai, Kanti, O’Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424415/
https://ncbi.nlm.nih.gov/pubmed/25755291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-585869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados